A phase 2 trial (NCT04291105) is underway in anti-PD-1/L1-refractory solid tumors, including advanced or metastatic melanoma; one study arm includes intratumoral and intravenous VV1 with intravenous cemiplimab in melanoma (Table 1). The gene discussed is PDCD1; the disease is melanoma.